Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma

Experimental Oncology

Volumn 27, Issue 2, 2005, Pages 159-161

  De Lucia, Domenico ^a   De Francesco, Francesco ^a   Marotta, Rosa ^a   Maisto, Giovanna ^a   Meo, Daniela ^a   Sessa, Marcella ^a   Misso, Margherita ^a   Galante, Maria ^a   Russo, Teresa ^a   Pignalosa, Orlando ^a   Napolitano, Mariasanta ^a   Papa, Maria Luisa ^b   Niglio, Alfeno ^a   Di Micco, Pierpaolo ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b San Giovanni Bosco Hospital   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Activated protein C resistance (APC r); Hypercoagulability; Non Hodgkin's lymphoma; Thrombophilic state

Indexed keywords

ACTIVATED PROTEIN C; ARGININE; BLOOD CLOTTING FACTOR 5; GENE PRODUCT; GENOMIC DNA; GLUTAMINE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BRAIN LYMPHOMA; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; HYPERCOAGULABILITY; MALE; NONHODGKIN LYMPHOMA; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PREDICTION; RISK FACTOR; STROKE; THROMBOPHILIA; TRANSIENT ISCHEMIC ATTACK;

ACTIVATED PROTEIN C RESISTANCE; BIOLOGICAL MARKERS; BLOOD COAGULATION; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; FACTOR V; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LYMPHOMA, NON-HODGKIN; MUTATION; PEPTIDE FRAGMENTS; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN;

EID: 22644445045     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Donati MB, Poggi A. Malignancy and haemostasis. Br J Haematol 1980; 44: 173-82.
2. De Lucia D, De Vita F, Orditura M, Renis V, Belli A, Conte M, di Grazia M, Iacoviello L, Donati MB, Catalano G. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidences for an acquired resistance to activated protein C. Tumori 1997; 83: 948-52.
3. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2001; 106: 6-12.
4. Piccioli A, Prandoni P. Venous thromboembolism as first manifestation of cancer. Acta Haematol 2001; 106: 13-7.
5. Di Micco P, De Lucia D, De Vita F, Niglio A, Di Micco G, Martinelli E, Chirico G, D'Uva M, Torella R. Acquired cancer-related thrombophilia testified by increased levels of prothrombin fragment 1 + 2 and D-dimer in patients affected by solid tumors. Exp Oncol 2002; 24: 108-11.
6. Mannucci PM. Markers of hypercoagulability in cancer patients. Haemostasis 1997; 27: 25-31.
7. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24: 5558-67.
8. Leone G, Sica S, Chiusolo P, Teofili L, De Stefano V. Blood cells diseases and thrombosis. Haematologica 2001; 86: 1236-44.
9. Di Micco P. Inside the two way clinical association between malignancy and alteration of haemostasis. Thromb Haemost 2005; 93: 1-2.
10. Hillen HF. Thrombosis in cancer patients Ann Oncol 2000; 11: 273-6.
11. Mailloux A, Grenet K, Bruneel A, Benetau Burnat B, Vaubourdolle M, Baudin B. Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol 2001; 80: 442-9.
12. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004; 50: 187-96.
13. Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 2003; 98: 1239-42.
14. Lui PCW, Wong GKC, Poon WS, Tse GMK. Intravascular lymphomatosis. J Clin Pathol 2003; 56: 468-70.
15. Dulli DA, Luzzio CC, Williams EC, Schutta HS. Cerebral venous thrombosis and activated protein C resistance. Stroke 1996; 27: 1731-33.
16. Leroy-Matheron C, Duvoux C, Van Nhieu JT, Leroy K, Cherqui D, Gouault-Heilmann M. Activated protein C resistance acquired through liver transplantation and associated with recurrent venous thrombosis. J Hepatol 2003; 38: 866-9.
17. De Lucia D, De Blasio G, Belli A, Conte M, Renis V, Di Mauro C, Tortora V, Valentini G. High prevalence of activated protein C resistance in patients with systemic sclerosis. Int J Clin Lab Res 1995; 25: 226-7.
18. Colucci M, Simioni P, Piro D, Prandoni P, Pagnan A, Semeraro N. An antifibrinolytic effect associated with an anti-factor V antibody in patient with severe thrombophilia. Haematologica 2003; 88: 1383.
19. Martinelli I, Battaglioli T, Mannucci PM. Combined estrogen-progestin oral contraceptives. N Engl J Med 2004; 350: 307-8.
20. Genvresse I, Luftner D, Spath-Schwalbe E, Buttgereit D. Prevalence and clinical significance of anticardiolipin and anti-beta2-glycoprotein-1 antibodies in patients with non-Hodgkin's lymphoma. Eur J Haematol 2002; 68: 84-90.
21. Nijziel MR, van Oerle R, Christella M, Thomassen LG, van Pampus EC, Hamulyak K, Tans G, Rosing J. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol 2003; 120: 117-22.
22. Landolsi A, Ben Fatma L, Ben Ammou S, Kallel L, Aloulou S, Gharbi O, Monastiri K, Kraiem C, Ben Ahmed S. Non-metastatic thrombosis of the superior sagittal sinus complicating Burkitt's lymphoma. A case report. Ann Med Interne 2003; 154: 67-9.
23. Di Micco P, Castaldo G, Granata G, Niglio A. Absence of activated protein C resistance in nonmetastatic gastric patients. Exp Oncol 2003; 25: 231-2.
24. Zacharski LR, Henderson WG, Rickles FR. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative study. Cancer 1984; 53: 2046-52.
25. Zacharski LR, Cosatntini V, Memoli V, Wojtukiawicz MZ, Ornestein DL. Clotting factors in tumor tissue: implications for cancer therapy. Blood Coagul Fibrinolysis 1990; 1: 71-8.